Migraine DisordersNCT05690737
Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration
A study testing Tai Chi training and Standard prophylactic medication in people with Migraine Disorders, run by The Hong Kong Polytechnic University at 2 sites in Hong Kong.
Trial summary
The proposed study aims to examine the clinical efficacy of 24-week Tai Chi training in the prophylaxis of episodic migraine comparing with standard prophylactic medication in Hong Kong Chinese women, and to explore the mechanism of Tai Chi's intervention effect by examining the associations of changes in migraine… Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Migraine Disorders
- What is being tested?
- Tai Chi training and Standard prophylactic medication
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 2 sitesHong Kong
- Study dates
- 11 Sep 2023to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chinese woman, aged 18-65 years.
- Have a clinical diagnosis of episodic migraine (migraine with less than 15 attacks per month) with or without aura according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).
- First migraine attack before the age of 45 years.
- Between two and six migraine attacks in one month.
- At least one of the following migraine characteristics is met: nausea, vomiting, photophobia, or phonophobia.
- Duration of migraine attacks is 2-72 h without acute medication or at least 1 h with acute medication.
- Able to undertake designated level of Tai Chi exercise.
- Live in Hong Kong.
Who cannot join
- Severe migraine attacks with disabilities that cannot perform moderate intensity physical activity.
- Secondary headache and other neurological disease.
- More than 5 days of non-migrainous headache per month.
- Experience with Tai Chi or other body-mind exercises (yoga, biofeedback, medication, etc.) after diagnosis of migraine.
- Undergoing other alternative therapeutic treatments during recruitment period, or received other alternative therapeutic treatments in the past 12 weeks.
- Pregnancy, lactation period, or currently using contraceptives.
Show all 9Show fewer
- Use of pharmacological prophylactic treatment for migraine in the past 12 weeks.
- Drug abuse, take antipsychotic or antidepressant drugs, or take analgesics for other chronic pain more than 3 days a month in the past 12 weeks.
- Epilepsy, or have a psychiatric disease.
Trial locations and contacts
2 sites in 1 country.
Hong Kong2 sites
The Hong Kong Polytechnic University
Hong Kong, HONG KONG
The Hong Kong Polytechnic University
Hung Hom
About this study
Official title: A Randomized Controlled Trail to Examine the Efficacy of Tai Chi for the Prophylaxis of Episodic Migraine Compared With Standard Prophylactic Medication in Chinese Women and a Pre-post Neuroimaging and Laboratory-based Study to Explore the Mechanism of Tai Chi's Intervention Effect
The proposed study aims to examine the clinical efficacy of 24-week Tai Chi training in the prophylaxis of episodic migraine comparing with standard prophylactic medication in Hong Kong Chinese women, and to explore the mechanism of Tai Chi's intervention effect by examining the associations of changes in migraine features with neurovascular and neuroinflammation variations.
Read the detailed description
A two-arm individual level randomized controlled trial is designed. A total of 220 local women diagnosed with episodic migraine between 18-65 years will be randomly assigned to one of two groups: 1) a Tai Chi training group receiving the 33-short form Yang-style Tai Chi training; or 2) a standard prophylactic medication group receiving the regular medication prescribed by the neurologist. The intervention period will be 24 weeks with another 24 weeks follow-up. The frequency of migraine attack, migraine days, intensity and duration of headache will be recorded by a migraine diary at the baseline, 24th weeks, and 48th weeks. Other outcomes including migraine related disability, stress, sleep quality, fatigue, and QOL will be measured at these three time points. The clinical efficacy will be determined by comparing the differences of outcomes from baseline to the end of the trial between two groups. The MRI and TCD will be used to measure the degree of white matter abnormality and cerebrovascular function, respectively; and the inflammatory markers will also be tested at three time points for Tai Chi participants. The mechanism of intervention effect will be explored by analyzing the changes and associations of migraine features with the process of these neurovascular functions and inflammatory markers during and after the Tai Chi training.
- Conditions
- Migraine Disorders
- Being tested
- Tai Chi training, Standard prophylactic medication
- Keywords
- Migraine, Tai Chi, Women, Mechanism, Prophylaxis
- Medical subject headings
- Migraine Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tai Chi trainingBehavioural
The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
Standard prophylactic medicationDrug
Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
| Study group | Role | What they receive |
|---|---|---|
| Tai Chi training | Experimental | The participants in this arm will receive 24-week Tai Chi training (1 hour per day, 5 days per week) with 24-week follow-up. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. Receives: Behavioral: Tai Chi training |
| Standard prophylactic medication | Active comparator | Participants in this arm will receive 48-week standard migraine prophylactic medication following neurologist's recommendation. Receives: Drug: Standard prophylactic medication |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in frequency of migraine attacks
The frequency of migraine attacks will be measured by the number of attacks per month.
Measured: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The difference in frequency of migraine days
The frequency of migraine days will be measured by the days with migraine attacks per month.
Measured: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The difference of white matter abnormalities (WMAs)
All the participants in the Tai Chi group will be measured with MRI. The appearance, number, size and location of WMAs will be recorded. Two experienced neurologists or neuroradiologists will be invited to review the MRI scans independently. Scheltens' visual rating scale will be used to measure the degree of WMAs. Briefly, WMAs will be separately graded in each of the following locations: frontal lobes, temporal lobes, parietal lobes and occipital lobes. WMAs will be graded as follows: 0 (no lesions), 1 (hyperintensity < 3 mm and n ≤ 5), 2 (< 3 mm and n ≥ 6), 3 (4-10 mm and n ≤ 5), 4 (4-10 mm and n ≥ 6), 5 (≥ 11 mm and n ≥ 1), and 6 (confluent). The sum of scores from each location will be considered as the final score. Only the women who are identified WMAs (Scheltens' visual rating scores >0) will take the MRI test again at the 24th week and 48th week.
Measured: From the baseline to 24 weeks and 48 weeks
The difference of pulsatility index (PI)
PI in all intracranial and neck vessels will be measured and recorded by Transcranial Doppler (TCD).
Measured: From the baseline to 24 weeks and 48 weeks
The difference of mean blood flow velocity (MBFV)
MBFV in all intracranial and neck vessels will be measured and recorded by Transcranial Doppler (TCD).
Measured: From the baseline to 24 weeks and 48 weeks
The difference of impaired cerebrovascular responsiveness (CVR).
The CVR will be calculated by: CVR=△MBFV=(Vstim-Vrest)/Vrest*100, where △MBFV is the relative change of blood flow velocity, Vstim is the blood flow velocity during the stimulation, and Vrest is the baseline flow velocity during the initial 5 min prior to stimulation. The value will be calculated by the mean of both left and right brain and from 10 cycles.
Measured: From the baseline to 24 weeks and 48 weeks
Secondary outcomes (17)
The proportion of responders
Defined as the proportion of patients with at least a 50% reduction of the number of attacks per month
Measured: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The intensity of the headache
The intensity of the headache measured by a Visual Analogue Scale (VAS). This scale is most commonly anchored by "no pain" (score of 0) and "worst imaginable pain" (score of 10). Higher scores indicate higher level of headache intensity.
Measured: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The duration of headache
The duration of headache recorded in the migraine diary to the nearest 0.1 hour.
Measured: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
Migraine related disability
Migraine related disability measured by the Migraine Disability Assessment Score (MIDAS). The MIDAS consists of five items that reflect the number of days reported as either missing or with reduced productivity at work, home, and social events in last 3 months and two additional items that assess the number of days with headaches in the last 3 months and a scale of the painfulness of the headaches. The MIDAS is scored as the sum of days reported in the first five questions. Higher scores are indicative of more disability.
Measured: From the baseline to 24 weeks and 48 weeks
Stress level
Stress level evaluated by the Perceived Stress Scale-14 (PSS-14). The total score of PSS-14 ranges from 0 to 56 with higher scores indicating higher perceived stress.
Measured: From the baseline to 24 weeks and 48 weeks
Sleep quality
Sleep quality examined by the Chinese version of the Pittsburgh Sleep Quality Index (PSQI). The global score of PSQI ranges from 0 to 21 with a higher score indicating worse sleep quality.
Measured: From the baseline to 24 weeks and 48 weeks
Fatigue level
Fatigue level evaluated by the Numeric Rating Scale-fatigue scale (NRS). NRS evaluates fatigue level at a 0-to-10 scale, with 0 indicating no fatigue and 10 indicating the worst possible fatigue.
Measured: From the baseline to 24 weeks and 48 weeks
Health related Quality-of-Life
Health related Quality-of-Life measured by the Migraine-Specific Quality-of-Life Questionnaire (MSQ). The total scores of MSQ range from 0-100, with a higher score indicating better Quality-of-Life.
Measured: From the baseline to 24 weeks and 48 weeks
Weight
Weight in kilograms
Measured: From the baseline to 24 weeks and 48 weeks
Height
Height in meters
Measured: From the baseline to 24 weeks and 48 weeks
Waist circumference
Waist circumference in cm
Measured: From the baseline to 24 weeks and 48 weeks
Hip circumference
Hip circumference in cm
Measured: From the baseline to 24 weeks and 48 weeks
Percent body fat
Percent body fat in %
Measured: From the baseline to 24 weeks and 48 weeks
TNF- α
The blood samples (10 ml) will be drawn from antecubital vein of all eligible participants by a research nurse. Serum is separated after centrifugation for 10 minutes at 2,000g and frozen at - 20 °C until assay. The serum sample will be sent to medical laboratories for testing by the Enzyme-linked immunosorbent assay (ELISA). TNF-α will be measured in pg/ml.
Measured: From the baseline to 24 weeks and 48 weeks
CGRP
The blood samples (10 ml) will be drawn from antecubital vein of all eligible participants by a research nurse. Serum is separated after centrifugation for 10 minutes at 2,000g and frozen at - 20 °C until assay. The serum sample will be sent to medical laboratories for testing by the Enzyme-linked immunosorbent assay (ELISA). CGRP will be measured in pg/ml.
Measured: From the baseline to 24 weeks and 48 weeks
CRP
The blood samples (10 ml) will be drawn from antecubital vein of all eligible participants by a research nurse. Serum is separated after centrifugation for 10 minutes at 2,000g and frozen at - 20 °C until assay. The serum sample will be sent to medical laboratories for testing by the Enzyme-linked immunosorbent assay (ELISA). CRP will be measured in pg/ml.
Measured: From the baseline to 24 weeks and 48 weeks
IL-6
The blood samples (10 ml) will be drawn from antecubital vein of all eligible participants by a research nurse. Serum is separated after centrifugation for 10 minutes at 2,000g and frozen at - 20 °C until assay. The serum sample will be sent to medical laboratories for testing by the Enzyme-linked immunosorbent assay (ELISA). IL-6 will be measured in pg/ml.
Measured: From the baseline to 24 weeks and 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jan 2023
- Study start11 Sep 2023
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Migraine DisordersStudies of the same condition, open and under way.
- More trials run by The Hong Kong Polytechnic UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 220 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Hong Kong Polytechnic University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, XIE Yao Jie Grace, The Hong Kong Polytechnic University
- Investigators
- Yao Jie Xie, PhD, Principal investigator, The Hong Kong Polytechnic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05690737
- Sponsor's protocol ID
- A0041948
- Status last verified
- Sep 2026
- First submitted
- 10 Jan 2023
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Xie YJ, Liao X, Hui SS, Tian L, Yeung WF, Lau AY, Tyrovolas S, Gao Y, Chen X. Tai Chi for the prophylaxis of episodic migraine: protocol of a non-inferiority randomized controlled trial with mechanism exploration. BMC Complement Med Ther. 2023 Sep 18;23(1):328. doi: 10.1186/s12906-023-04154-x.
PubMed 37723467
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trail to Examine the Efficacy of Tai Chi for the Prophylaxis of Episodic Migraine Compared With Standard Prophylactic Medication in Chinese Women and a Pre-post Neuroimaging and Laboratory-based Study to Explore the Mechanism of Tai Chi's Intervention Effect
- ClinicalTrials.gov ID
- NCT05690737
- Acronym / sponsor ID
- A0041948
- Conditions
- Migraine Disorders
- Keywords
- Migraine, Tai Chi, Women, Mechanism, Prophylaxis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 220 participants (actual)
- Lead sponsor
- The Hong Kong Polytechnic UniversityUniversity, hospital or other
- Study start
- 11 Sep 2023 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 19 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed study aims to examine the clinical efficacy of 24-week Tai Chi training in the prophylaxis of episodic migraine comparing with standard prophylactic medication in Hong Kong Chinese women, and to explore the mechanism of Tai Chi's intervention effect by examining the associations of changes in migraine features with neurovascular and neuroinflammation variations.
Detailed description
A two-arm individual level randomized controlled trial is designed. A total of 220 local women diagnosed with episodic migraine between 18-65 years will be randomly assigned to one of two groups: 1) a Tai Chi training group receiving the 33-short form Yang-style Tai Chi training; or 2) a standard prophylactic medication group receiving the regular medication prescribed by the neurologist. The intervention period will be 24 weeks with another 24 weeks follow-up. The frequency of migraine attack, migraine days, intensity and duration of headache will be recorded by a migraine diary at the baseline, 24th weeks, and 48th weeks. Other outcomes including migraine related disability, stress, sleep quality, fatigue, and QOL will be measured at these three time points. The clinical efficacy will be determined by comparing the differences of outcomes from baseline to the end of the trial between two groups. The MRI and TCD will be used to measure the degree of white matter abnormality and cerebrovascular function, respectively; and the inflammatory markers will also be tested at three time points for Tai Chi participants. The mechanism of intervention effect will be explored by analyzing the changes and associations of migraine features with the process of these neurovascular functions and inflammatory markers during and after the Tai Chi training.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tai Chi training | Experimental | Behavioral: Tai Chi trainingThe participants in this arm will receive 24-week Tai Chi training (1 hour per day, 5 days per week) with 24-week follow-up. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. |
| Standard prophylactic medication | Active comparator | Drug: Standard prophylactic medicationParticipants in this arm will receive 48-week standard migraine prophylactic medication following neurologist's recommendation. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Chinese woman, aged 18-65 years.
- Have a clinical diagnosis of episodic migraine (migraine with less than 15 attacks per month) with or without aura according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).
- First migraine attack before the age of 45 years.
- Between two and six migraine attacks in one month.
- At least one of the following migraine characteristics is met: nausea, vomiting, photophobia, or phonophobia.
Key exclusion criteria (9 listed)
- Severe migraine attacks with disabilities that cannot perform moderate intensity physical activity.
- Secondary headache and other neurological disease.
- More than 5 days of non-migrainous headache per month.
- Experience with Tai Chi or other body-mind exercises (yoga, biofeedback, medication, etc.) after diagnosis of migraine.
- Undergoing other alternative therapeutic treatments during recruitment period, or received other alternative therapeutic treatments in the past 12 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tai Chi trainingThe 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves. | Behavioural | Tai Chi training |
| Standard prophylactic medicationParticipants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly. | Drug | Standard prophylactic medication |
Primary outcome
The difference in frequency of migraine attacks
Time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The frequency of migraine attacks will be measured by the number of attacks per month.
The difference in frequency of migraine days
Time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The frequency of migraine days will be measured by the days with migraine attacks per month.
The difference of white matter abnormalities (WMAs)
Time frame: From the baseline to 24 weeks and 48 weeks
All the participants in the Tai Chi group will be measured with MRI. The appearance, number, size and location of WMAs will be recorded. Two experienced neurologists or neuroradiologists will be invited to review the MRI scans independently. Scheltens' visual rating scale will be used to measure the degree of WMAs. Briefly, WMAs will be separately graded in each of the following locations: frontal lobes, temporal lobes, parietal lobes and occipital lobes. WMAs will be graded as follows: 0 (no lesions), 1 (hyperintensity < 3 mm and n ≤ 5), 2 (< 3 mm and n ≥ 6), 3 (4-10 mm and n ≤ 5), 4 (4-10 mm and n ≥ 6), 5 (≥ 11 mm and n ≥ 1), and 6 (confluent). The sum of scores from each location will be considered as the final score. Only the women who are identified WMAs (Scheltens' visual rating scores >0) will take the MRI test again at the 24th week and 48th week.
The difference of pulsatility index (PI)
Time frame: From the baseline to 24 weeks and 48 weeks
PI in all intracranial and neck vessels will be measured and recorded by Transcranial Doppler (TCD).
The difference of mean blood flow velocity (MBFV)
Time frame: From the baseline to 24 weeks and 48 weeks
MBFV in all intracranial and neck vessels will be measured and recorded by Transcranial Doppler (TCD).
The difference of impaired cerebrovascular responsiveness (CVR).
Time frame: From the baseline to 24 weeks and 48 weeks
The CVR will be calculated by: CVR=△MBFV=(Vstim-Vrest)/Vrest*100, where △MBFV is the relative change of blood flow velocity, Vstim is the blood flow velocity during the stimulation, and Vrest is the baseline flow velocity during the initial 5 min prior to stimulation. The value will be calculated by the mean of both left and right brain and from 10 cycles.
17 secondary outcomes
The proportion of responders
Time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The intensity of the headache
Time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
The duration of headache
Time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization
Migraine related disability
Time frame: From the baseline to 24 weeks and 48 weeks
Stress level
Time frame: From the baseline to 24 weeks and 48 weeks
Sleep quality
Time frame: From the baseline to 24 weeks and 48 weeks
Fatigue level
Time frame: From the baseline to 24 weeks and 48 weeks
Health related Quality-of-Life
Time frame: From the baseline to 24 weeks and 48 weeks
Weight
Time frame: From the baseline to 24 weeks and 48 weeks
Height
Time frame: From the baseline to 24 weeks and 48 weeks
Waist circumference
Time frame: From the baseline to 24 weeks and 48 weeks
Hip circumference
Time frame: From the baseline to 24 weeks and 48 weeks
Percent body fat
Time frame: From the baseline to 24 weeks and 48 weeks
TNF- α
Time frame: From the baseline to 24 weeks and 48 weeks
CGRP
Time frame: From the baseline to 24 weeks and 48 weeks
CRP
Time frame: From the baseline to 24 weeks and 48 weeks
IL-6
Time frame: From the baseline to 24 weeks and 48 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Derived from this study: PubMed 37723467Xie YJ, Liao X, Hui SS, Tian L, Yeung WF, Lau AY, Tyrovolas S, Gao Y, Chen X. Tai Chi for the prophylaxis of episodic migraine: protocol of a non-inferiority randomized controlled trial with mechanism exploration. BMC Complement Med Ther. 2023 Sep 18;23(1):328. doi: 10.1186/s12906-023-04154-x.
- Individual participant dataSharing planned: No
Related trials for Migraine Disorders
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yao Jie Xie, PhD principal investigator
The Hong Kong Polytechnic University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tai Chi training and Standard prophylactic medication in people with Migraine Disorders, run by The Hong Kong Polytechnic University at 2 sites in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in frequency of migraine attacks (time frame: Between 4 weeks before randomization and weeks 21-24 / 45-48 after randomization). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05690737, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.